Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Feb
22
Today In Oncology
FLIPI24: New Prognostic Model for Newly Diagnosed Follicular Lymphoma
Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers
CLL/SLL FDA Approves Combination of Acalabrutinib and Venetoclax
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo